Published on
May 19, 2021

HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

Natural Health Products Will Be Manufactured and Packaged at the Company's New Facility

VANCOUVER, BC / ACCESSWIRE / May 19, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a production and supply agreement (the "Agreement") with Lobe Sciences Ltd. (LOBE) (GTSIF), an innovative biotech company committed to investigating and developing treatments using psychedelic and non-traditional medicines for better brain health.

Pursuant to the Agreement, HAVN Life will produce and supply an offering of Natural Health Products ("NHP"), which will include plant-based compounds and non-psychoactive mushrooms. The Agreement with Lobe Sciences will create an additional revenue stream for HAVN Life, and the team will look to generate additional agreements in the coming months.

The Agreement comes at a pivotal moment for HAVN Life, as the Company prepares to launch its e-commerce site and begin executing its Canada wide distribution strategy for its initial proprietary natural health product offerings following the acquisition of its production and warehousing facility in Richmond B.C. Leveraging the Company's new production and warehousing facility, its e-commerce platform, and its Canada-wide distribution strategy, HAVN Life is poised to quickly strengthen its presence in the natural health products space.

In March, HAVN Life acquired the strategic manufacturing and packaging facility to support production of its initial retail product offerings and scale production of new formulations. As the Company prepares for the launch of its line of proprietary natural health products next month, the announcement of the Agreement creates an additional revenue stream. With both its owned brands and white-labelled products, HAVN Life will maintain its commitment to ensuring the highest standards of quality and efficacy.

"We're thrilled to enter into this Agreement with a company that shares our mission of finding novel ways to support brain health," said HAVN Life CEO Tim Moore. "Not only does the release of these products provide an immense growth opportunity for HAVN Life, but it ultimately moves use towards our main goal of optimizing human performance."

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Lobe Sciences Ltd.

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

About HAVN Life Sciences Inc.

HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: and follow us on Facebook, Twitter, Instagram and Youtube.


Investor Relations: 604 687 7130
Media: 647 896-8078

Cautionary Note Regarding Forward-Looking Statements

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Acquisition, the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the Acquisition will not be completed as contemplated, or at all, risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release